Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 9/20 | 0.79 |
| ▸ | HTR2C known ✓ | P28335 | 2/20 | 0.50 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.49 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.48 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.47 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.47 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 10/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | SPR | P35270 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5164757 | 0.99 | OPRL1 (0.79) | OPRL1OPRM1KDM4EMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL5164725 | 0.89 | OPRL1 (0.81) | OPRL1OPRM1MEN1KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL5164886 | 0.89 | OPRL1 (1.00) | OPRL1OPRM1SLC6A4HTR2ANOTUM | |
| SCHEMBL5166857 | 0.88 | OPRL1 (0.80) | OPRL1OPRM1MEN1KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL5165408 | 0.88 | OPRL1 (1.00) | OPRL1OPRM1KDM4EMEN1KMT2A | |
| SCHEMBL5163332 | 0.87 | OPRL1 (1.00) | OPRL1OPRM1SLC6A4NOTUM | |
| SCHEMBL5163716 | 0.87 | OPRL1 (1.00) | OPRL1OPRM1KDM4EMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL5166426 | 0.87 | OPRL1 (0.77) | OPRL1OPRM1ACHEALDH1A1LMNA | |
| SCHEMBL5165980 | 0.86 | OPRL1 (0.76) | OPRL1OPRM1MEN1KMT2AACHE | |
| SCHEMBL5164068 | 0.84 | OPRL1 (0.71) | OPRL1OPRM1KDM4ESLC6A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1533374-B | Substitutled cyclohexane-1,4-diamine derivatives | GRUENETHAL GMBH | 2013-08-21 | — | — | CN | claimed |
| US-7276518-B2 | Substituted cyclohexane-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2007-10-02 | — | — | US | claimed |
| EP-1392641-B1 | SUBSTITUTED CYCLOHEXANE-1,4-DIAMINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2007-04-11 | — | — | EP | claimed |
| CN-1533374-A | Substitutled cyclohexane-1,4-diamine derivatives | — | 2004-09-29 | — | — | CN | claimed |
| US-20040162287-A1 | Substituted cyclohexane-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2004-08-19 | — | — | US | claimed |
| EP-1392641-A1 | SUBSTITUTED CYCLOHEXANE-1,4-DIAMINE DERIVATIVES | Grünenthal GmbH (DE) | 2004-03-03 | — | — | EP | claimed |
| WO-2002090317-A1 | SUBSTITUTED CYCLOHEXANE-1,4-DIAMINE DERIVATIVES | Grünenthal GmbH (DE) | 2002-11-14 | — | — | WO | claimed |
| CN-1533374-B | Substitutled cyclohexane-1,4-diamine derivatives | GRUENETHAL GMBH | 2013-08-21 | — | — | CN | disclosed |
| US-7276518-B2 | Substituted cyclohexane-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2007-10-02 | — | — | US | disclosed |
| EP-1392641-B1 | SUBSTITUTED CYCLOHEXANE-1,4-DIAMINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2007-04-11 | — | — | EP | disclosed |
| US-20040229872-A1 | Substituted cyclohexane-1,4-diamine compounds with anti-diarrhea and peripheral analgesic activity | GRUENENTHAL GMBH (DE) | 2004-11-18 | — | — | US | disclosed |
| CN-1533374-A | Substitutled cyclohexane-1,4-diamine derivatives | — | 2004-09-29 | — | — | CN | disclosed |
| US-20040162287-A1 | Substituted cyclohexane-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2004-08-19 | — | — | US | disclosed |
| EP-1392641-A1 | SUBSTITUTED CYCLOHEXANE-1,4-DIAMINE DERIVATIVES | Grünenthal GmbH (DE) | 2004-03-03 | — | — | EP | disclosed |
| EP-1385493-A1 | SUBSTITUTED CYCLOHEXAN-1,4-DIAMINE DERIVATIVES WITH CONSTIPATING AND PERIPHERAL ANALGESIC PROPERTIES | Grünenthal GmbH (DE) | 2004-02-04 | — | — | EP | disclosed |
| WO-2002090317-A1 | SUBSTITUTED CYCLOHEXANE-1,4-DIAMINE DERIVATIVES | Grünenthal GmbH (DE) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002089783-A1 | SUBSTITUTED CYCLOHEXAN-1,4-DIAMINE DERIVATIVES WITH CONSTIPATING AND PERIPHERAL ANALGESIC PROPERTIES | Grünenthal GmbH (DE) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162287-A1 | Substituted cyclohexane-1,4-diamine compounds | DPYD, DDC, QDPR | OPRM1 459/4885HTR2C 247/4885ACHE 952/4885 |
| US-20040229872-A1 | Substituted cyclohexane-1,4-diamine compounds with anti-diarrhea and peripheral analgesic activity | ARG1, CD2, PDCD1 | OPRM1 250/4885HTR2C 1917/4885ACHE 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.